ImmunoGen (IMGN) Pops Higher Following Positive T-DM1 Phase III Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
ImmunoGen (Nasdaq: IMGN) is moving higher ahead of the bell Friday following positive results from its T-DM1 EMILIA Phase III trial. Shares are indicated about 12 percent higher.
T-DM1 (trastuzumab emtansine) consists of ImmunoGen's potent cancer-killing agent, DM1, attached to the HER2-targeting antibody.
For more color on the results, click here.
T-DM1 (trastuzumab emtansine) consists of ImmunoGen's potent cancer-killing agent, DM1, attached to the HER2-targeting antibody.
For more color on the results, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lumentum's optical components sold out through early 2029: CEO
- Musk rules out TSMC role in Terafab operations; Intel gains
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
